Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens stock plummeted 56% in 2024, and is now trading below $12 a share. Quarterly dividend now yields 8%+, providing a potential opportunity for robust passive income. Challenges in the operating environment require new approach, potential store closures and divestitures in the future.

Walgreens: Yielding Over 8% Following The Earnings Drop

NEW YORK, NY / ACCESSWIRE / July 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Did Walgreens Boots Alliance, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - WBA

WBA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Walgreens Boots Alliance, Inc.

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In WBA Can Participate In The Securities Fraud Probe Of Walgreens Boots Alliance, Inc. With The Schall Law Firm

DEERFIELD, Ill.--(BUSINESS WIRE)--Today, Walgreens announced its participation for the second year as a sponsor of Children with Diabetes (CWD), a nonprofit organization dedicated to providing education and support to families living with type 1 diabetes, at their upcoming Friends for Life (FFL) conference. Walgreens will showcase several offerings and healthcare solutions for diabetes at the annual event, hosted July 9-14 in Orlando, Fla. FFL gathers dedicated experts, adults, children, and fa.

Walgreens Strengthens Support for Children and Adults Living with Diabetes

Levi Strauss

NIKE

Blue-chip stocks continue to trail in this market. Through the first half of the year, the Dow Jones Industrial Average, which is comprised of 30 blue-chip stocks, is up 4% compared to a 20% gain in the technology loaded Nasdaq Composite index.

3 Blue-Chip Stocks to Sell in July Before They Crash & Burn

Walgreens Boots Alliance, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - WBA

Margin pressures and lowered guidance paint a challenging picture for the company's shares in the near term.

Bear of the Day: Walgreens Boots Alliance (WBA)

Lululemon Athletica

Tesla

It will be tough for the stock market to keep up the pace after such an explosive first half. Undoubtedly, stocks could easily continue to rise if demand for artificial intelligence accelerates further.

3 Overhyped Stocks to Sell in July Before They Crash & Burn

Walgreens Boots Alliance is looking to reduce its investment in the doctor-staffed clinic operator VillageMD after billions of dollars in losses and the need to focus on more profitable ventures to turn around the drugstore chain.

After Billions In Losses, Walgreens Doesn't Want To Own VillageMD

An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.

Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down

As Walgreens Boots Alliance considers closing hundreds of “underperforming” stores, the company's top executive says a turnaround of the drugstore giant's key U.S. retail pharmacy business could take several “quarters, not months.”

As Walgreens Closes Stores, Turnaround May Take ‘Quarters, Not Months'

CVS Health

Rite Aid Corp

For years, U.S. pharmacy chains have been shuttering locations around the nation. It's a trend one industry expert says will continue, especially with the demand for online pharmacies.

CVS, Walgreens, Rite Aid closing stores: a brick and mortar downfall?

Seb James, CEO of Boots since 2018, will leave the company in November, as its owner postponed a multibillion-pound sale for the second time. James will become the group CEO of Veonet, the European ophthalmology clinic chain.

Boots boss quits after float is shelved by ailing Walgreens

Head of Boots pharmacy chain reportedly will depart as owner Walgreens struggles.

Head of Boots pharmacy chain reportedly will depart as Walgreens struggles

Walgreens shares plunged after the company lowered its EPS guidance. The company has been experiencing severe drug reimbursement pressures, hurting margins and profitability.

Walgreens Stock Collapses on Weak Outlook. Is Now the Time to Buy?

Walgreens Boots Alliance stock fell hard after the company reported fiscal third-quarter results on June 27. Management has lowered its earnings expectations twice this year.

Down Over 60%, Is Walgreens Boots Alliance a Bad-News Buy?

Super Micro Computer

The tech stock ended June trading with a 2024 gain of 188%, while the pharmacy chain has fallen 54%.

Super Micro Computer Led the S&P in the First Half. Walgreens Was the Top Loser.

Walgreens (NASDAQ: WBA) has experienced a significant decline in 2023, with shares down over 55% year-to-date, trading at levels last seen in 1998.

Walgreens Stock Price Collapses

After years of a downtrend in their price, shares of Walgreens Boots Alliance Inc. NASDAQ: WBA have thrown in the towel this time. In a single day, the stock is down over 25% in a sign that can't be taken in any other way than a ‘run' message.

What's Behind Walgreens Stock Plunge: What Investors Can Do Next

Walgreens is one of the most celebrated names in the retail pharmacy space, boasting innovation and convenience for its customers. However, in its latest earnings report, the company announced a tough financial environment and outlook, citing “a worse-than-expected U.S. consumer environment.

Walgreens' Challenges With Stores And VillageMD Prove Just How Tough Healthcare Is

Boots chain CEO Sebastian James quit as CEO after owner Walgreens Boots Alliance's plans for a 5 billion pound ($6.32 billion) sale or stock market listing of the company stalled, Sky News reporter Mark Kleinman said in a post on X on Saturday.

Boots CEO James quits after Walgreens' plans for sale stalls, Sky News reporter says

Akamai Technologies

Albemarle

Boeing

Charter Communications

Dayforce Inc

Dollar Tree

Estee Lauder

EPAM Systems

Etsy

Globe Life Inc

Global Payments

Intel

MarketAxess Holdings

Paramount Global

Paycom Software

Warner Bros Discovery Inc

The S&P 500 is up nearly 16% so far this year with dividends reinvested. Artificial intelligence has been the big theme driving gains for Big Tech, especially Nvidia Corp. But 38% of the S&P 500 have had negative returns during the first half of 2024.

These 20 stocks have been the S&P 500's biggest losers so far in 2024

Inflation Comes in as Expected

Q2's expected quarterly earnings growth pace of +8.3% reflects the strongest growth since back in Q1 of 2022. Tech is expected to do some heavy lifting again, with earnings expected to be up +15.5% on +9.5% higher revenues.

News for Walgreens Stock (WBA)